Entering text into the input field will update the search result below

Antinuclear Antibody Testing Market Worth $1,476.1 Million – High Incidence Of Autoimmune Diseases

May 10, 2021 8:49 AM ETBio-Rad Laboratories, Inc. (BIO)
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.


  • High Incidence of Autoimmune Diseases.
  • Growth in the Number of Individuals Covered Under Medical Insurance.

The report aims to provide insights into the global antinuclear antibody test market. It provides valuable information on the products, techniques, and diseases in the ANA testing market. Details on regional markets for these segments are also presented in this report. Also, leading players are profiled to study their product offerings and understand the strategies undertaken by them to be competitive in this market.

The report “Antinuclear Antibody Test Market by Product (Reagents & Assay Kits, Systems, Software, Services), Technique (Immunofluorescence, Elisa, Multiplex), Disease (Rheumatoid Arthritis, SLE), End User (Clinical Labs, Hospitals) – Forecast to 2021″, report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the ANA testing market, along with revenue estimates & forecasts and market share analysis.

Expected Revenue Surge:

The Global Antinuclear Antibody Test Market is expected to reach USD 1,476.1 Million, at a CAGR of 12.4%

Request Research Sample Pages: Antinuclear Antibody Test Market

Market Segmentation in Detailed:

Based on techniques, the antinuclear antibody test market is segmented into three broad segment, namely, enzyme-linked immunosorbent assay (ELISA), immunofluorescence assay (IFA), and multiplex assay. The ELISA segment is expected to account for the largest share of this market owing to expanding applications of ANA in autoimmune disease testing and therapeutic drug level monitoring.

The end-user segments in this market include clinical laboratories, hospitals, POLs, and other end users. The hospitals segment is expected to account for the largest share in 2016, primarily due to the rising healthcare spending which has resulted in a growth in use of ANA testing products in hospitals. Based on region, the global antinuclear antibody test market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share of the market during the forecast period. Growth in this regional segment is driven by factors such as rising geriatric population and increasing prevalence of autoimmune diseases.

Geographical View in-detailed:

North America is the largest regional segment in the ANA testing market, followed by Europe, Asia, and the Rest of the World (RoW). Growth in the North American market is primarily driven by the high incidence of autoimmune diseases, growing population and healthcare spending, and growth in the number of individuals covered under medical insurance in the U.S.

Download PDF Brochure: Antinuclear Antibody Test Market

Global Key Leaders:

Key players in the antinuclear antibody test market include Alere Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), ERBA Diagnostics, Inc. (U.S.), Trinity Biotech plc (Ireland), Thermo Fisher Scientific, Inc. (U.S.), Antibodies, Inc. (U.S.), EUROIMMUN AG (Germany), Immuno Concepts (U.S.), Inova Diagnostics (U.S.), and Zeus Scientific, Inc. (U.S.).

Bio-Rad Laboratories, Inc. (U.S.) is the third-largest player in the global ANA testing market, with a share of 9.5% in 2014. Bio-Rad caters to the life science research and clinical diagnostics market by developing and supplying novel products and services. The company’s product portfolio comprises analysis kits, reagents, and systems for antinuclear antibody testing. It focuses on new product launches and acquisitions as its key growth strategies.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.